|Day Low/High||57.81 / 63.78|
|52 Wk Low/High||44.17 / 87.54|
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
The major indices barely budged intraday this week, as we had the narrowest trading range ever.
It's hard to be too negative considering the speculative action today.
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
U.S. stocks saw slow action ahead of the start of a Fed meeting and a big East Coast snow storm Tuesday.
This group has had some excellent speculative action lately while not much else has been working.
The markets' focus will be on the pace of future interest rate hikes.
We end the week with the same question we had at the start.
Why the name is sagging, and what it will take to spur the sector higher.
Let's take a look at several stocks that are experiencing unusual volume activity.
It is clear that tax policy isn't going to be solidified in a couple of weeks.
But it is all about timing, and so far there is no indication that this extended market is about to turn.
It will be interesting to see today if afternoon strength occurs once again.
Finding new buys becomes more difficult, and knowing when to lock in gains isn't easy, either.
You can feel the misery of those who are struggling with feelings of being left behind.
Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.
If the indices take out yesterday's lows I'll be very bearish very quickly.
Good picks make it easier to produce good results, but they are just a starting point.
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.